{
    "nct_id": "NCT05446870",
    "official_title": "A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer",
    "inclusion_criteria": "* Has histologically-confirmed International Federation of Gynecology and Obstetrics (FIGO) Stage III or Stage IV HGSOC, primary peritoneal cancer, or fallopian tube cancer.\n* Is a candidate for carboplatin and paclitaxel chemotherapy, to be administered in the neoadjuvant and adjuvant setting.\n* Is a candidate for interval debulking surgery.\n* Is able to provide archival tissue or newly obtained core, incisional, or excisional biopsy of a tumor lesion.\n* Has adequate organ functions.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has a non-HGSOC histology.\n* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Has received prior treatment for any stage of OC, including radiation or systemic anticancer therapy.\n* Planned or has been administered intraperitoneal chemotherapy as first-line therapy.\n* Has received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death 1 ligand 1 (PD-L1), anti-programmed cell death 1 ligand 2 (PD-L2), anti-immunoglobulin-like transcript 4 (ILT4), or anti-human leukocyte antigen (HLA)-G agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor.\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication.\n* Has known active Central Nervous System (CNS) metastases and/or carcinomatous meningitis.\n* Has severe hypersensitivity to pembrolizumab, carboplatin, paclitaxel (or docetaxel, if applicable), Avastin or biosimilar (if using) and/or any of their excipients.\n* Has an active autoimmune disease that has required systemic treatment in past 2 years.\n* Has an active infection requiring systemic therapy.\n* Has a known history of human immunodeficiency virus (HIV) infection.\n* Has a known history of hepatitis B or known active hepatitis C virus infection.\n* Has received colony-stimulating factors within 4 weeks prior to receiving study intervention on Day 1 of Cycle 1.\n* Has had surgery <6 months prior to Screening to treat borderline ovarian tumors, early-stage OC, or early-stage fallopian tube cancer.\n* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.\n* Has current, clinically relevant bowel obstruction.\n* Has a history of hemorrhage, hemoptysis, or active gastrointestinal (GI) bleeding within 6 months prior to randomization.\n* Has uncontrolled hypertension.\n* Has had an allogenic tissue/solid organ transplant.\n* .Has either had major surgery within 3 weeks of randomization or has not recovered from any effects of any major surgery.",
    "miscellaneous_criteria": "The main inclusion and exclusion criteria include but are not limited to the following:"
}